RECRUITING

Minimal Residual Disease Assessment in Patients with Colorectal Cancer, the MiRDA-C Study

Talk to us

Conditions

Colorectal AdenocarcinomaStage I Colorectal Cancer AJCC V8Stage II Colorectal Cancer AJCC V8Stage IIA Colorectal Cancer AJCC V8Stage IIB Colorectal Cancer AJCC V8Stage IIC Colorectal Cancer AJCC V8Stage III Colorectal Cancer AJCC V8Stage IIIA Colorectal Cancer AJCC V8Stage IIIB Colorectal Cancer AJCC V8Stage IIIC Colorectal Cancer AJCC V8Stage IV Colorectal Cancer AJCC V6Stage IVA Colorectal Cancer AJCC V8Stage IVB Colorectal Cancer AJCC V8Stage IVC Colorectal Cancer AJCC V8

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.

Official Title

Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)

Quick Facts

Study Start:2019-11-22
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04739072

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age ≥ 18 years.
  2. 2. Histological/cytological confirmation of colorectal adenocarcinoma.
  3. 3. Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
  4. 4. Ability to understand and the willingness to sign a written informed consent document.
  5. 5. Willing to pursue standard of care surveillance post completion of curative therapies.
  6. 6. Willing to provide blood samples for correlative research.
  1. 1. Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
  2. 2. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Contacts and Locations

Study Contact

Arvind Dasari
CONTACT
(713) 792-2828
adasari@mdanderson.org

Principal Investigator

Arvind Dasari
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

Banner - MD Anderson Cancer Center
Gilbert, Arizona, 85234
United States
Baptist- MD Anderson Cancer Center
Jacksonville, Florida, 32207
United States
The Queen's Medical Center
Honolulu, Hawaii, 96813
United States
St. Luke's Cancer Institute
Boise, Idaho, 83712
United States
Cooper Hospital UNIV MED CTR.
Camden, New Jersey, 08103
United States
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
United States
Houston Methodist Cancer Center
Houston, Texas, 77030
United States
M D Anderson Cancer Center
Houston, Texas, 77030
United States
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas, 78229
United States
Baylor Scott & White Research Institute
Temple, Texas, 76508
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Arvind Dasari, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-11-22
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2019-11-22
Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Colorectal Adenocarcinoma
  • Stage I Colorectal Cancer AJCC V8
  • Stage II Colorectal Cancer AJCC V8
  • Stage IIA Colorectal Cancer AJCC V8
  • Stage IIB Colorectal Cancer AJCC V8
  • Stage IIC Colorectal Cancer AJCC V8
  • Stage III Colorectal Cancer AJCC V8
  • Stage IIIA Colorectal Cancer AJCC V8
  • Stage IIIB Colorectal Cancer AJCC V8
  • Stage IIIC Colorectal Cancer AJCC V8
  • Stage IV Colorectal Cancer AJCC V6
  • Stage IVA Colorectal Cancer AJCC V8
  • Stage IVB Colorectal Cancer AJCC V8
  • Stage IVC Colorectal Cancer AJCC V8